Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St Jude makes US and EU progress with HF (heart failure) ICDs (implantable cardioverter defibrillator):

This article was originally published in Clinica

Executive Summary

St Jude Medical has gained the green light from the US FDA to begin a clinical study of its implantable device for treating heart failure (HF). The Epic HF model V-338 implantable cardioverter defibrillator (ICD), which combines pacemaker therapy, defibrillation therapy, and left-heart stimulation, will be assessed in patients suffering from both heart failure and ventricular tachyarrhythmias. In a separate announcement, the St Paul, Minnesota firm said that it had CE-marked for sale in Europe another HF device from its Epic product line - the Epic HF model V-339 ICD. St Jude already markets in Europe a HF device called Genesis.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT067155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel